Thomas J Lynch

Summary

Affiliation: Yale University
Country: USA

Publications

  1. doi request reprint Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
    Thomas J Lynch
    Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA
    J Clin Oncol 30:2046-54. 2012
  2. doi request reprint Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099
    Thomas J Lynch
    Yale School of Medicine, 333 Cedar St, PO Box 208028, New Haven, CT 06520, USA
    J Clin Oncol 28:911-7. 2010
  3. doi request reprint A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
    Thomas J Lynch
    Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Thorac Oncol 4:1002-9. 2009
  4. ncbi request reprint The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms
    Geoffrey Liu
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer 101:2802-8. 2004
  5. ncbi request reprint XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
    Sarada Gurubhagavatula
    Department of Medicine, Massachusetts General Hospital, Boston, MA USA
    J Clin Oncol 22:2594-601. 2004
  6. ncbi request reprint Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients
    Wei Zhou
    Departments of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    J Clin Oncol 25:479-85. 2007
  7. ncbi request reprint Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians
    Li Lian Xu
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 11:1555-9. 2002
  8. ncbi request reprint Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk
    Wei Zhou
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 12:359-65. 2003
  9. ncbi request reprint Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
    Rebecca Suk
    Massachusetts General Hospital and Harvard School of Public Health, Boston, MA 02115, USA
    Clin Cancer Res 11:1534-8. 2005
  10. pmc Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk
    Rihong Zhai
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Carcinogenesis 29:2330-4. 2008

Detail Information

Publications89

  1. doi request reprint Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
    Thomas J Lynch
    Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA
    J Clin Oncol 30:2046-54. 2012
    ..A phase II study in lung cancer assessed the activity of ipilimumab plus paclitaxel and carboplatin...
  2. doi request reprint Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099
    Thomas J Lynch
    Yale School of Medicine, 333 Cedar St, PO Box 208028, New Haven, CT 06520, USA
    J Clin Oncol 28:911-7. 2010
    ..There was significant improvement in ORR by IRRC. The difference in OS favored cetuximab but did not reach statistical significance...
  3. doi request reprint A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
    Thomas J Lynch
    Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Thorac Oncol 4:1002-9. 2009
    ..This phase 2 study was conducted to determine the efficacy and safety of erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC)...
  4. ncbi request reprint The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms
    Geoffrey Liu
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer 101:2802-8. 2004
    ..p53 is a tumor suppressor gene, and X-ray cross-complementing group 1 (XRCC1) is involved in the base-excision repair of ROS-induced DNA damage...
  5. ncbi request reprint XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
    Sarada Gurubhagavatula
    Department of Medicine, Massachusetts General Hospital, Boston, MA USA
    J Clin Oncol 22:2594-601. 2004
    ..Genetic polymorphisms of DNA repair genes are associated with differential DNA repair activity and may explain interindividual differences in overall survival after therapy with platinum agents for non-small-cell lung cancer (NSCLC)...
  6. ncbi request reprint Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients
    Wei Zhou
    Departments of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    J Clin Oncol 25:479-85. 2007
    ..We further investigated the results of circulating 25-hydroxyvitamin D (25[OH]D) levels on overall survival (OS) and recurrence-free survival (RFS) in NSCLC patients...
  7. ncbi request reprint Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians
    Li Lian Xu
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 11:1555-9. 2002
    ..These findings are in contrast with earlier studies suggesting a protective effect of carrying the variant A allele...
  8. ncbi request reprint Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk
    Wei Zhou
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 12:359-65. 2003
    ..In conclusion, cumulative cigarette smoking plays an important role in altering the direction and magnitude of the associations between the XRCC1 and ERCC2 polymorphisms and lung cancer risk...
  9. ncbi request reprint Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
    Rebecca Suk
    Massachusetts General Hospital and Harvard School of Public Health, Boston, MA 02115, USA
    Clin Cancer Res 11:1534-8. 2005
    ..Polymorphisms have been identified in the ERCC1 gene, the C8092A and codon 118 polymorphisms, which may lead to an altered capacity to regenerate damaged normal tissue and greater treatment-related toxicity...
  10. pmc Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk
    Rihong Zhai
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Carcinogenesis 29:2330-4. 2008
    ..70; 95% CI, 1.04-2.73; P = 0.034). These results suggested that cigarette smoking modifies the association between VEGF polymorphisms and EA risk among Caucasians...
  11. pmc Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, USA
    J Clin Oncol 26:5596-602. 2008
    ..We hypothesized that vitamin D levels and VDR polymorphisms may also affect survival among patients with advanced NSCLC...
  12. ncbi request reprint MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma
    Geoffrey Liu
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Lett 214:69-79. 2004
    ..For women carrying the MPO variant genotypes, the adjusted odds ratio of the SOD2 polymorphism (Val/Val vs. Ala/Ala) was 3.26 (95% CI, 1.55-6.83). No associations were found in men or in women carrying the MPO GG wildtype genotype...
  13. ncbi request reprint Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Wei Zhou
    Occupational Health Program, Departments of Environmental Health and Biostatistics, Harvard School of Public Health, Boston 02115, Massachusetts, USA
    Clin Cancer Res 10:4939-43. 2004
    ..9 (T/T), 16.1 (C/T), and 13.3 (C/C) months, respectively. In conclusion, the ERCC1 C8092A polymorphism may be a useful predictor of OS in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy...
  14. doi request reprint First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
    ..The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms...
  15. ncbi request reprint No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk
    Li Su
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 12:174-5. 2003
  16. ncbi request reprint Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients
    Wei Zhou
    Departments of Environmental Health, Occupational Health Program, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 15:2239-45. 2006
    ..71). Similar associations were found in haplotype analysis and for RFS among SCC patients. In conclusion, VDR polymorphisms may be associated with improved survival among SCC patients of early-stage NSCLC...
  17. doi request reprint Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors
    Cameron D Wright
    Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Ann Thorac Surg 85:385-9. 2008
    ..Our center adopted an alternative strategy and treated locally advanced thymic tumors with induction chemoradiotherapy in an effort to maximize the intensity of the induction therapy...
  18. ncbi request reprint Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients
    Wei Zhou
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Clin Cancer Res 12:7187-93. 2006
    ..Second hand smoke (SHS) exposure is associated with higher risk of lung cancer. However, the role of SHS in lung cancer survival is not clear...
  19. ncbi request reprint XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk
    Geoffrey Liu
    Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Carcinogenesis 28:1254-8. 2007
    ..No relationships were found for the XPD Asp312Asn polymorphism. We conclude that combined NER and BER pathways are important to the development of EA...
  20. ncbi request reprint Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School Partners Healthcare Center for Genetics and Genomics, MGH Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Oncologist 12:90-8. 2007
    ..6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information...
  21. ncbi request reprint Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer
    Wei Zhou
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:491-6. 2005
    ..In conclusion, ERCC1 8092C > A polymorphism may modify the associations between cumulative cigarette smoking and lung cancer risk...
  22. ncbi request reprint P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21
    Li Su
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Lung Cancer 40:259-66. 2003
    ..Results were consistent in both patients with lung cancer (n=63) and in normal controls (n=21). In conclusion, the presence of a p53 Pro allele and/or p21 Arg allele is associated with lower downstream target gene expression of p21...
  23. ncbi request reprint Association between self-reported environmental tobacco smoke exposure and lung cancer: modification by GSTP1 polymorphism
    David P Miller
    Department of Environmental Heath, Occupational Health Program, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 104:758-63. 2003
    ..Furthermore, the presence of the GSTP1 GG genotype appears to enhance the magnitude of the association between ETS exposure and lung cancer. Larger studies will be needed to confirm these preliminary findings...
  24. doi request reprint VEGF polymorphisms and survival in early-stage non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 26:856-62. 2008
    ..Polymorphisms in the VEGF gene have been identified that are believed to have functional activity. We hypothesized that such polymorphisms may affect survival outcomes among early-stage non-small-cell lung cancer (NSCLC) patients...
  25. ncbi request reprint Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk
    Li Su
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:567-70. 2005
    ..00-1.75; 1G/2G) and 1.23 (95% CI, 0.88-1.73; 2G/2G) in males, respectively. In conclusion, genotypes containing the 2G allele of the MMP-1 polymorphism are associated with higher risk of lung cancer in never-smokers and in males...
  26. pmc EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    April F Eichler
    Pappas Center for Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Neuro Oncol 12:1193-9. 2010
    ..70-6.41) were independently associated with survival. In NSCLC patients with BM, EGFR mutation status is associated with improved survival, independent of age, functional status, extracranial disease status, and number of BMs...
  27. ncbi request reprint Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    John R Goffin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:3417-24. 2005
    ..A phase I study was initiated to determine whether conventional doses of carboplatin and paclitaxel are tolerated when combined with marimastat and to assess the influence of marimastat on paclitaxel pharmacokinetics...
  28. pmc A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
    ..This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer...
  29. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  30. ncbi request reprint Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 25:587-95. 2007
    ....
  31. ncbi request reprint Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital and Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:5448-53. 2006
    ..We hypothesized that polymorphisms in these MMP genes may be associated with survival outcomes in early-stage non-small cell lung cancer (NSCLC)...
  32. doi request reprint Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Joel W Neal
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 5:1855-8. 2010
    ..Cetuximab is a monoclonal antibody against the EGFR receptor with antitumor activity in NSCLC. This study evaluated the efficacy of cetuximab monotherapy after prior treatment with an oral EGFR tyrosine kinase inhibitor (TKI)...
  33. doi request reprint A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer
    Rebecca Suk Heist
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Thorac Oncol 3:1153-8. 2008
    ..We investigated the activity and tolerability of the combination of oxaliplatin, pemetrexed, and bevacizumab in patients with previously treated advanced NSCLC...
  34. ncbi request reprint A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Invest 24:229-34. 2006
    ..The use of doxorubicin as an alternative to epirubicin in the ECF regimen has not been evaluated...
  35. ncbi request reprint Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms
    David P Miller
    Department of Environmental Heath, Occupational Health Program, Harvard School of Public Health, Boston, MA 02115, USA
    Epidemiology 14:545-51. 2003
    ..We examined the interaction between GSTP1 polymorphisms and cumulative exposure to smoking and their association with lung cancer risk...
  36. doi request reprint Aggressiveness of care in a prospective cohort of patients with advanced NSCLC
    Jennifer S Temel
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 113:826-33. 2008
    ..Optimal end of life care of patients with terminal cancer is poorly understood. In this study, the aggressiveness of care is described in a cohort of patients with newly diagnosed advanced nonsmall-cell lung cancer (NSCLC)...
  37. ncbi request reprint Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:760-6. 2007
    ..The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement...
  38. ncbi request reprint Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients
    Wei Zhou
    Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
    Lung Cancer 53:375-80. 2006
    ..In conclusion, smoking cessation is associated with improved survival in early stage NSCLC patients. The longer the time since cessation of smoking, the better the survival outcome...
  39. ncbi request reprint Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus
    Cameron D Wright
    General Thoracic Surgical Unit, Massachusetts General Hospital, Boston 02114, USA
    Ann Thorac Surg 73:1541-4. 2002
    ..Induction chemoradiotherapy (CT/RT) has been shown to reduce local and distant recurrences and improve survival in stage III lung cancer. We investigated the role of induction CT/RT in superior sulcus patients...
  40. ncbi request reprint Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer
    Li Su
    Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
    Carcinogenesis 27:1024-9. 2006
    ..62-8.20) when compared with the most common 1G-5A-82A-1082A haplotype. In conclusion, the combined MMP genotypes and associated haplotypes may be associated with higher risk of lung cancer, particularly among never smokers and men...
  41. ncbi request reprint Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    ..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib...
  42. ncbi request reprint Dietary iron, zinc, and calcium and the risk of lung cancer
    Wei Zhou
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, and the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Epidemiology 16:772-9. 2005
    ..Dietary intakes of these micronutrients have been associated with altered risks of colorectal, breast, and prostate cancers...
  43. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  44. doi request reprint Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer
    Panos Fidias
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1156-62. 2009
    ....
  45. ncbi request reprint Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer
    Kevin S Roof
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:1120-8. 2006
    ..This article updates our experience with PFT-R, and compares these results to our experience with cisplatin, 5-FU, and radiation therapy (PF-R) in locally advanced esophageal cancer...
  46. ncbi request reprint MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2243-7. 2007
    ..We hypothesized that the MDM2 G/G genotype may be associated with worse survival outcomes in lung cancer, especially in squamous cell cancers where p53 abnormalities are more common...
  47. ncbi request reprint Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer
    Wei Zhou
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Res 62:1377-81. 2002
    ..A stronger gene-smoking interaction was observed for the Asp312Asn polymorphism than for the Lys751Gln polymorphism. In conclusion, cumulative cigarette smoking modifies the associations between ERCC2 polymorphisms and lung cancer risk...
  48. ncbi request reprint An association between glutathione S-transferase P1 gene polymorphism and younger age at onset of lung carcinoma
    David P Miller
    Department of Environmental Heath, Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts, USA
    Cancer 107:1570-7. 2006
    ..The variant GSTP1 GG genotype is associated with lower enzymatic activity and higher DNA adduct levels in human lymphocytes compared with the AA genotype...
  49. ncbi request reprint Hope
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Yawkey 9066, 55 Fruit Street, Boston, Massachusetts 02114 2617, USA
    Oncologist 12:1105-13. 2007
    ..The literature and limited evidence base are reviewed...
  50. doi request reprint Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1389-96. 2009
    ..We aimed to evaluate the safety and efficacy of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer...
  51. doi request reprint Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 28:3076-83. 2010
    ..Resistance emerges after 9 to 12 months, primarily mediated by the T790M resistance mutation. We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M...
  52. doi request reprint Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1170-3. 2009
    ..7 months, and median overall survival was 3.9 months. We found that biweekly pemetrexed and gemcitabine was too toxic in our cohort of elderly patients with newly diagnosed advanced non-small cell lung cancer...
  53. pmc Connection: Schwartz Center Rounds at Massachusetts General Hospital Cancer Center
    Richard T Penson
    M R C P, Hematology Oncology, Yawkey 9064, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 15:760-4. 2010
    ..In this article we explore the reasons that contribute to the success of this model of multidisciplinary reflection...
  54. ncbi request reprint Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients
    Wei Zhou
    Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:2303-9. 2005
    ..In conclusion, the joint effects of surgery season and recent vitamin D intake seem to be associated with the survival of early-stage non-small cell lung cancer patients...
  55. ncbi request reprint Teams: communication in multidisciplinary care
    Richard T Penson
    The Kenneth B Schwartz Center at Massachusetts General Hospital, Department of Medicine, Boston, Massachusetts 02114 2617, USA
    Oncologist 11:520-6. 2006
    ..This article explores the tough issue of how teams handle uncertainty and bad news and how patients and families can be better supported in the multifaceted paradigm of modern care...
  56. doi request reprint Early palliative care for patients with metastatic non-small-cell lung cancer
    Jennifer S Temel
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 363:733-42. 2010
    ..We examined the effect of introducing palliative care early after diagnosis on patient-reported outcomes and end-of-life care among ambulatory patients with newly diagnosed disease...
  57. ncbi request reprint Direct-to-consumer advertising in oncology
    Gregory A Abel
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
    Oncologist 11:217-26. 2006
    ..Although sparse, the medical literature on this increasingly prevalent type of medical communication is also reviewed...
  58. doi request reprint Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 5:1637-43. 2010
    ..AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC...
  59. ncbi request reprint Learning to cope: how far is too close?
    Brian M Wolpin
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 10:449-56. 2005
    ..To conclude, further educational initiatives are advocated to assist both physicians-in-training and more senior clinicians in dealing with the difficult issues that arise when caring for very ill and dying patients...
  60. ncbi request reprint Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk
    David P Miller
    Department of Environmental Heath, Occupational Health Program, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Cancer Res 62:2819-23. 2002
    ..03 (95% CI, 1.47-11.1); for the P1-p53 DV the AOR was 5.10 (95% CI, 1.42-18.30). Specific DVs of GSTM1, GSTP1, and p53 codon 72 are associated with a higher lung cancer risk. This susceptibility is highest among younger individuals...
  61. doi request reprint Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study
    William F Pirl
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Psychosomatics 49:218-24. 2008
    ..Major depressive disorder is estimated to occur in 10%-25% of people with cancer, and it has been inconsistently linked to increased mortality...
  62. doi request reprint Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care
    Jennifer S Temel
    Massachusetts GeneralHospital Cancer Center, 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 29:2319-26. 2011
    ..The aims of this study were to explore perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer (NSCLC) and to examine the effect of early palliative care on these views over time...
  63. ncbi request reprint Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors
    Johanna C Bendell
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 103:1925-31. 2005
    ..The purpose of the current open-label, Phase I dose-escalation trial was to evaluate the combination of tezacitabine and 5-fluorouracil (5-FU) in the treatment of patients with advanced solid tumors...
  64. doi request reprint A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
    Kwok K Wong
    Dana Farber Cancer Institute, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:2552-8. 2009
    ..The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were determined in patients with advanced solid tumors...
  65. ncbi request reprint FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology
    Jin Sook Ryu
    Division of Nuclear Medicine, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 32 Fruit St, Boston, MA, USA
    Lung Cancer 35:179-87. 2002
    ..For the primary lesions, SUV based analysis has high sensitivity but limited specificity for detecting residual tumor. In contrast, for restaging of mediastinal lymph nodes, FDG-PET is highly specific, but has limited sensitivity...
  66. ncbi request reprint The role of adjuvant chemotherapy for non-small cell lung cancer
    Sarada Gurubhagavatula
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Semin Respir Crit Care Med 26:298-303. 2005
    ..10 study. From these collective studies, a new standard of care has emerged in the treatment of early-stage resected NSCLC: the use of adjuvant platinum-based chemotherapy...
  67. pmc Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer
    Rebecca A Miksad
    Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 27:2245-52. 2009
    ..This study provides a clinically relevant example of Bayesian methods...
  68. doi request reprint The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    J Thorac Oncol 4:281-3. 2009
    ..Here, we review the development and initial clinical studies with a novel microfluidic platform for isolating these cells, the CTC-chip, and discuss its potential uses in the study of lung cancer...
  69. ncbi request reprint A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
    Leena Gandhi
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 109:924-32. 2007
    ..A Phase II study was designed to evaluate VX-710 in combination with doxorubicin and vincristine in patients with sensitive, recurrent small cell lung cancer (SCLC)...
  70. ncbi request reprint Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1234, Boston, MA 02115, USA
    Lung Cancer 44:221-30. 2004
    ....
  71. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2004. A 56-year-old woman with cough and a lung nodule
    Thomas J Lynch
    Department of Medical Oncology, Massachusetts General Hospital, USA
    N Engl J Med 351:809-17. 2004
  72. doi request reprint Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer
    Inga T Lennes
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Clin Lung Cancer 10:341-6. 2009
    ..Proposed quality metrics focus on diagnosis and staging, timeliness of care, supportive care and patient satisfaction...
  73. doi request reprint Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  74. doi request reprint Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer
    Akash Nanda
    Harvard Radiation Oncology Program, Boston Medical Center, Boston, MA 02114, USA
    Clin Lung Cancer 9:285-7. 2008
    ..It also highlights the potential risks of molecular targeted radiation therapy...
  75. ncbi request reprint Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology and Dana Farber Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Clin Cancer Res 11:4981s-4983s. 2005
  76. ncbi request reprint Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA
    Clin Cancer Res 11:5668-70. 2005
  77. ncbi request reprint Living as a cancer surpriser: a doctor tells his story
    Kristine A Knuti
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 8:108-22. 2003
    ..In addition to such processes, patient-caregivers with cancer also find that their own medical knowledge and their colleagues' reactions shape their experiences and to an extent separate them from those of other patients...
  78. ncbi request reprint Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer
    Jennifer S Temel
    Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Lung Cancer 7:241-9. 2006
    ..Therefore, comprehensive care of patients with advanced-stage NSCLC must include therapies targeted at these difficult and distressing symptoms...
  79. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  80. ncbi request reprint Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    Lecia V Sequist
    Cancer Center and Department of Medicine, Massachusetts General Hospital, and Laboratory for Molecular Medicine, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:4403s-4408s. 2006
    ..It is likely that mutation testing and other molecular analyses will be most useful in these two clinical situations...
  81. pmc A structured exercise program for patients with advanced non-small cell lung cancer
    Jennifer S Temel
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:595-601. 2009
    ..In this study, we examined the feasibility of a hospital-based exercise program for patients with advanced non-small cell lung cancer...
  82. ncbi request reprint Radiation dose escalation in limited-stage small-cell lung cancer
    Kevin S Roof
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02116, USA
    Int J Radiat Oncol Biol Phys 57:701-8. 2003
    ....
  83. ncbi request reprint Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients
    Jennifer S Temel
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 25:2377-82. 2007
    ..To assess the feasibility of early palliative care in the ambulatory setting in patients with newly diagnosed advanced non-small-cell lung cancer (NSCLC)...
  84. ncbi request reprint Predictive tests for EGFR inhibitors
    Thomas J Lynch
    Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 3:678-9. 2005
  85. ncbi request reprint Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors
    Jeffrey G Supko
    Massachusetts General Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 9:5178-86. 2003
    ..A Phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic behavior of KRN5500 given as a 1-h i.v. infusion for 5 consecutive days every 3 weeks...
  86. ncbi request reprint Trust violated: analgesics for addicts
    Richard T Penson
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
    Oncologist 8:199-209. 2003
    ..With open and honest support, the team was able to both care for and empower the patient. Issues of trust, liability, opioid tolerance, and barriers to optimal analgesia for cancer pain are discussed...
  87. doi request reprint Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC
    Nathan A Pennell
    Massachusetts General Hospital, Boston, MA, USA
    Oncologist 14:399-411. 2009
    ..Ongoing phase II and phase III trials will determine the clinical potential of a number of dual inhibition strategies in the treatment of advanced NSCLC...
  88. ncbi request reprint Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  89. ncbi request reprint Building a better therapy for stage IIIA non-small cell lung cancer
    Tracey L Evans
    Dana Farber Partners Cancer Care, Harvard Medical School, Hematology Oncology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Chest Med 23:191-207. 2002
    ..Trimodality therapy remains a promising but unproved approach in patients with stage IIIA disease. With the exciting new molecularly targeted agents, trials examining quad-modality therapy are just around the corner...